- Monitoring:
* Liver functionality in patients with symptoms of liver damage.
No specific problems have been reported in elderly people forcing a dosing readjustment.
- Call your doctor if symptoms continue after 7 days of treatment, or if new symptoms such as high or persistent fever, shortness of breath or mucus with blood appear.
- Tell your doctor and/or pharmacist if you experience any of these symptoms:
* Acute and intense pain in the upper right abdomen, nausea and vomiting, loss of appetite, unwarranted tiredness, darkening of urine or appearance of yellowish hue on the skin or white of the eyes.
- Hypersensitivity to pelargonium or any other component of the medicine.
- Patients with severe bleeding or elevated bleeding trends (see Precautions; clotting disorders).
- Concomitant treatment with anticoagulants (see Interactions; anticoagulants).
- Severe liver or kidney disease.
No studies have been conducted, although it is unlikely to affect driving.
Animal safety: no data available.
Human safety: adequate and well-controlled human studies are not available. It is not recommended for use during pregnancy.
Effects on fertility: no specific human studies have been conducted.
- Symptomatic treatment of [COMMON COLD] in adults, adolescents and children > 6 years.
Its indication is based exclusively on traditional use.
- Oral anticoagulants. Pelargonium may alter blood clotting, favoring bleeding. Contraindicated use.
Animal safety: no data available.
Human safety: It is not known whether its components are excreted with milk, and the consequences they could have for the infant. It is not recommended for use during lactation.
Authorized in children and adolescents from 6 years of age, with corresponding dosing adjustments (see Posology).
Safety and efficacy in children < 6 years have not been evaluated, so it is recommended to avoid their use.
- Syrup: drink with some liquid in the morning, noon and night.
Syrup:
- Adults and adolescents > 12 years: 7.5 milliliters 3 times a day (morning, afternoon and night).
- Children 6-12 years: 5 milliliters 3 times a day (morning, afternoon and night).
- Children < 6 years: not recommended.
- Elderly: no specific dosage recommendations have been made.
Duration of treatment: continue treatment 7 days, and may be extended for an additional 2-3 days to avoid relapses. If symptoms continue or worsen after 7 days, consult your doctor. The maximum duration is 14 days.
Forgetting doses: administer the next dose at the usual time. Do not double the next dose.
No specific dosing recommendations have been made. Its use is contraindicated in severe renal pathologies.
No specific dosing recommendations have been made. Its use is contraindicated in severe renal pathologies.
- [HEPATOTOXICITY]. Cases of hepatitis have been reported following the use of Pelargonium. In case of suspected hepatotoxicity, discontinue treatment and monitor liver functionality.
- [COAGULATION ALTERATIONS]. Pelargonium may promote bleeding, so it should be used with caution in patients prone to [HEMORRAGIA].
Adverse reactions are described according to each frequency interval, considered very common (>10%), common (1-10%), uncommon (0.1-1%), rare (0.01-0.1%), very rare (<0.01%) or of unknown frequency (cannot be estimated from the available data).
- Digestives: Uncommon [ABDOMINAL PAIN], [GASTRIC HYPERACIDEZ], [NAUSEAS], [DIARREA].
- Hepatic: unknown frequency [HEPATOTOXICITY], [HEPATITIS].
- Allergic: rare [HYPERSENSITIVITY REACTIONS], with [EXANTEMATIC ERUPTIONS], [URTICARIA], [PRURITO]; very rare facial oedema, [DYSPNOEA] or [HIPOTENSION].
- Haematological: rare [GINGIVAL HEMORRAGIA], [EPISTAXIS].
Symptoms: No cases have been reported.
Measures to be taken:
- Antidote: there is no specific antidote.
- General elimination measures: have not been established.
- Monitoring: clinical condition of the patient and liver function.
- Treatment: symptomatic.